GENE THERAPY VECTOR PRODUCTION
The increasing number of gene therapy-based discovery programs in the biotech and pharma industry is driving a greater need for the scalable production of gene therapy vectors.
Our suspension CAP-GT cell lines provide a novel platform for the industrial production of viral vectors. CAP-GT cell lines are fully documented and comply with regulatory requirements. Growing in serum-free suspension culture at high densities, the cells provide a fully scalable vector production platform.